No access
SIG 6 Hearing and Balance Sciences: Research and Clinical Applications
Article
September 2005

Audiological Monitoring of Patients Receiving Ototoxic Drugs

Publication: Perspectives on Hearing and Hearing Disorders: Research and Diagnostics
Volume 9, Number 1
Pages 17-22
First page of PDF

Get full access to this article

View all available purchase options and get full access to this article.

References

ASHA. (1994). Guidelines for the audiologic management of individuals receiving cochleotoxic drugtherapy. Asha, 36 (Suppl. 12), 11–19.
ASHA. (2004). Ototoxic drugs can damage hearing. Retrieved July 5, 2005, from www.asha.org/about/news/tipsheets/ototoxic
Barron, S. E., & Daigneault, E. A. (1987). Effect of cisplatin on haircell morphology and lateral wall Na, K-ATPase activity. Hearing Research, 26, 131–137.
Beattie, R. C., Kenworthy, O. T., & Luna, C.A. (2003). Immediate and short-term reliability of distortion-product otoacoustic emissions. International Journal of Audiology, 42, 348–354.
Bertolini, P., Lassalle, M., Mercier, G., Raquin, M. A., Izzi, G., Corradini, N., & Hartmann, O. (2004). Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. Journal of Pediatric Hematology/Oncology, 26, 649–655.
Black, F. O., & Pesznecker, S. C. (1993). Vestibularototoxicity. Clinical considerations. Otolaryngologic Clinics of North America, 26, 713–736.
Blakley, B. W., & Myers, S. F. (1993). Patterns of hearing loss resulting from cis-platinum therapy. Otolaryngology–Head and Neck Surgery, 109, 385–391.
Blakley, B. W., Gupta, A. K.,Myers, S.F., & Schwan, S. (1994). Risk factors for ototoxicity due to cisplatin. Archives of Otolaryngology–Head and Neck Surgery, 120, 541–546.
Brown, J. J., Brummett, R. E., Fox, K .E., & Bendrick, T. W. (1980). Combined effects of noise and kanamycin. Cochlear pathology and pharmacology. Archives of Otolaryngology, 106, 744–750.
Brummett, R. E. (1980). Drug-induced ototoxicity. Drugs, 19, 412–428.
Brummett, R. E., & Fox, K. E. (1982). Studiesof aminoglycoside ototoxicity in animal models. In A. Whelton & H .C. Neu (Eds.), The Aminoglycosides (pp. 419–451). New York: Marcel Dekker.
Burk, M. H., & Wiley, T. L. (2004). Continuous versus pulsed tones in audiometry. American Journal of Audiology, 13, 54–61.
DeLauretis, A., DeCapua, B., Barbieri, M. T., Bellussi, L., & Passali, D. (1999). ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin. Scandinavian Audiology, 28, 139–143.
Durrant, J. D., Rodgers, G., Meyers, E. N., & Johnson, J. T. (1990). Hearing loss-risk factor for cisplatin ototoxicity? Observations. American Journal of Otology, 11, 375–377.
Fausti, S. A., Helt, W. J., Phillips, D. S., Gordon, J. S., Bratt, G. W., Sugiura, K. M., & Noffsinger, D. (2003). Early detection of ototoxicity using 1/6th octavesteps. Journalofthe AmericanAcademyof Audiology, 14, 444–450.
Fausti, S. A., Henry, J. A., Helt, W. J., Phillips, D. S., Frey, R. H., Noff-singer, D., Larson, V. D., & Fowler, C. G. (1999). An individualized, sensitive frequency rangefor early detection of ototoxicity. Ear & Hearing, 20, 497–505.
Fausti, S. A., Henry, J. A., Schaffer, H. I., Olson, D. J., Frey, R. H., & Bagby, G.C. (1993). High-frequency monitoring for early detection of cisplatin ototoxicity. Archives of Otolaryngology Head & Neck Surgery, 119, 661–665.
Fausti, S. A., Henry, J. A., Schaffer, H. I., Olson, D. J., Frey, R. H., & McDonald, W. J. (1992). Early detection of aminoglycoside ototoxicity by high-frequency (³ 8 kHz) auditory evaluation. Journal of Infectious Disease, 165, 1026–1032.
Forge, A., & Schacht, J. (2000). Aminoglycoside antibiotics. Audiology & Neuro-otology, 5, 3–22.
Franklin, D. J., McCoy, M. J., Martin, G. K., & Lonsbury-Martin, B. L. (1992). Test/retest reliability of distortion-product and transiently evoked otoacoustic emissions. Ear and Hearing, 13, 417–429.
Gordon, J. S., Phillips, D., Helt, W. J., Konrad-Martin, D., & Fausti, S. A. (inpress). Evaluation of insert earphones for high-frequency bedside ototoxicity monitoring. Journal of Rehabilitation Research & Development.
Hodges, A. V., & Lonsbury-Martin, B. L. (1998). Hearing management. In P. A. Sullivan & A. M. Guilford (Eds.), Best practices in oncology management: Focus on swallowing and communication disorders (pp. 269–290). San Diego, CA: Singular Press.
Lonsbury-Martin, B. L., & Martin, G. K. (2001). Evoked otoacoustic emissions as objective screeners for ototoxicity. Seminars in Hearing, 22, 377–391.
Roede, J., Harris, F. P., Probst, R., & Xu, L. (1993). Repeatability of distortion product otoacoustic emissions in normally hearing humans. Audiology, 32, 273–281.
Rougier, F., Claude, D., Maurin, M., Sedoglavic, A., Ducher, M., Corvaisier, S., Jelliffe, R., & Maire, P. (2003). Aminglycoside nephrotoxicity:Modeling,simulation,and control. Antimicrobial Agents & Chemotherapy, 47, 1010–1016.
Simpson, T. H., Schwan, S. A., & Rintelmann, W. F. (1992). Audiometric test criteria in the detection of cisplatin ototoxicity. Journal of the American Academy of Audiology, 3, 176–185.
Stavroulaki, P., Apostolopoulos, N., Segas, J., Tsakanikos, M., & Adamopoulos, G. (2001). Evoked otoacoustic emissions—An approach for monitoring cisplatin induced ototoxicity in children. International Journal of Pediatric Otorhinolaryngology, 59, 47–57.

Information & Authors

Information

Published In

Perspectives on Hearing and Hearing Disorders: Research and Diagnostics
Volume 9Number 1September 2005
Pages: 17-22

History

  • Published in issue: Sep 1, 2005

Permissions

Request permissions for this article.

Authors

Affiliations

Dawn Konrad-Martin
Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical Center Portland, OR
Department of Otolaryngology, Oregon Health & Science University Portland, OR
Jane S. Gordon
Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical Center Portland, OR
Kelly M. Reavis
Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical Center Portland, OR
Debra J. Wilmington
Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical Center Portland, OR
Wendy J. Helt
Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical Center Portland, OR
Stephen A. Fausti
Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical Center Portland, OR
Department of Otolaryngology, Oregon Health & Science University Portland, OR

Metrics & Citations

Metrics

Article Metrics
View all metrics



Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Citing Literature

  • Ototoxicity: Cochleotoxicity and Vestibulotoxicity, Neurotology Updates, 10.1007/978-3-031-77370-9_23, (479-518), (2024).
  • The Impact of Monoclonal Antibody Usage on Hearing Outcomes: A Systematic Review, The Laryngoscope, 10.1002/lary.31763, 135, 2, (491-506), (2024).
  • Antibacterial Agents for Pediatric Infections, and Hearing Loss, Hearing Loss in Congenital, Neonatal and Childhood Infections, 10.1007/978-3-031-38495-0_69, (1051-1063), (2023).
  • Extended high-frequency audiometry in research and clinical practice, The Journal of the Acoustical Society of America, 10.1121/10.0009766, 151, 3, (1944-1955), (2022).
  • A Tale of Two Susceptibilities: Cisplatin Ototoxicity Variability in Similar Patients, Perspectives of the ASHA Special Interest Groups, 10.1044/2022_PERSP-21-00191, 7, 6, (1782-1791), (2022).
  • Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease, American Journal of Ophthalmology, 10.1016/j.ajo.2022.02.015, 240, (1-13), (2022).
  • Ototoxicity: A review of South African studies, South African Family Practice, 10.4102/safp.v63i1.5187, 63, 1, (2021).
  • Audiological monitoring of patients undergoing multidrug resistant tuberculosis treatment at Jigme Dorji Wangchuk National Referral Hospital and Gidakom Hospital, Bhutan, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 10.1016/j.jctube.2021.100229, 23, (100229), (2021).
  • Drug‐induced hearing loss: a case/non‐case study in the French pharmacovigilance database, Fundamental & Clinical Pharmacology, 10.1111/fcp.12533, 34, 3, (397-407), (2020).
  • Embedded Ear Care: Audiology on the Cancer Treatment Team, The ASHA Leader Archive, 10.1044/leader.FTR2.24102019.54, 24, 10, (54-59), (2019).

Figures

Tables

Media

Share

Share

Copy the content Link

Share